MedTrace Logo

Everolimus and LongActing Octreotide Trial in Polycystic Livers

NCT01157858 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2015-06-29

No results posted yet for this study

Summary

The aim of this study is to reduce polycystic liver volume by treating with octreotide, whether or not combined with everolimus; to assess whether combination therapy of everolimus and octreotide gives a bigger reduction of polycystic liver volume than octreotide monotherapy.

Conditions

  • Polycystic Liver Disease

Interventions

DRUG

Everolimus

2.5 mg every day orally

DRUG

Octreotide LAR

40 mg every 28 days IM

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Joost PH Drenth, MD, PhD · Radboud University Medical Center

  • Melissa Chrispijn, MD · Radboud University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01157858 on ClinicalTrials.gov